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Nutritional management of a critically injured patient
Introduction
A 28-year-old male patient was admitted with a gunshot wound in 
the abdomen. The gunshot wound was on the right iliac fossa, just 
above the right iliac crest, with no exit wound. The patient suffers 
from asthma and has a history of smoking.
Case report
During examination on admission (day 0), the patient was 
haemodynamically unstable, but responsive to fluids. He had a 
distended abdomen with decreased bowel sounds and was taken 
to theatre for an explorative laparotomy. Complete transection of the 
iliac vein was found and ligation was carried out. The external iliac 
artery had a long, devitalised segment for which the right groin was 
exposed to gain distal access. Use of a synthetic graft was indicated 
to repair the injury. Obtaining the graft from another hospital caused a 
delay, resulting in prolonged ischaemic time. Eventually the graft was 
used and an end-to-end anastomosis performed from the external 
proximal iliac artery to the common femoral artery. Small bowel 
lacerations were also found and closed. An angiogram was carried 
out to confirm the patency of the superficial femoral artery. Muscles 
of the right leg were considered borderline in terms of viability, and 
fasciotomies were executed. The patient was then admitted to the 
intensive care unit (ICU) on inotropes and full ventilation.
On day 2, a weak, but positive, dorsalis pedis pulse could be felt and 
the patient was taken back to theatre for a “relook” fasciotomy. The 
lateral compartment muscles were necrotic and debridement was 
carried out. On day 3, serum levels of myoglobin and creatine kinase 
(CK) had increased markedly, and on days 4 and 6, haemodialysis 
was introduced to treat fluid overload and myoglobinuria (Table I).
On day 5, extensive debridement of the lateral compartment was 
performed to remove necrotic tissue. Further debridement of the 
proximal and distal muscles had to be performed on day 7. The 
patient was taken to theatre for wound inspection on day 9, as serum 
myoglobin and CK levels had again increased, but the muscles in 
all the compartments were found to be viable. The patient was 
extubated on day 10 and transferred to the high care unit on day 
11. Eventually, an above-knee amputation had to be performed on 
day 14. The patient then recovered well and was transferred to the 
surgical ward on day 18. On day 22, he was discharged from hospital.
Diagnosis
The diagnosis was critical injury, related to an abdominal gunshot 
wound to the right iliac artery and prolonged ischaemic time, which 
eventually led to an above-knee amputation. Small bowel lacerations 
were closed, with no complications.
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Table I: Serum myoglobin and creatine kinase levels
Day 0 1 2 3 4 5 6 8 9 12 13 14 15 18 20
S-myoglobin
(16-96 µg/l)
1 451 37 160 15 383 6 420 2 878 1 529 735 320 1 093 173 319 309 1 325 338 159
S-CK
(20-200 U/l)
- - - 20 106 13 240 7 411 3 272 1 264 3 163 512 1 048 1 986 - - 706
Comment PO PD PD
Post
AKA
AKA: above-knee amputation, PD: post dialysis, PO: postoperative
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Anthropometry
Recumbent height was measured as 173 cm. The patient’s left mid-
arm circumference was 31.8 cm (50th percentile) and his weight was 
estimated at 75 kg with a body mass index value of 25 kg/m2. This 
correlated well with his clinical appearance. 
Nutritional management
Key considerations in the nutritional therapy of ICU patients include 
route of feeding (parenteral, enteral or both), when to feed (within 
24-48 hours, and preferably early enteral nutrition), and what to feed 
(standard feeds or feeds with pharmaconutrients).1
From admission, the dietitian was involved in the patient’s care 
as a multidisciplinary approach is a standard of care in the ICU in 
which the patient was treated. Table II provides a summary of the 
nutritional management of the patient, which will then be discussed 
in more detail.
Table II: Summary of nutritional management in the intensive care unit
Day 0 1 2 3 4 5 6 7 8 9 10 11
Intervention
Intravenous glutamine ü ü ü ü ü ü ü ü ü ü ü ü
Total parenteral nutrition ü ü ü ü ü ü ü ü ü
Trophic feeds (nasogastric) ü ü ü ü ü
Full enteral feeds ü ü ü ü
Oral feeds ü
Upon admission to the ICU (day 0), the dietitian requested the start 
of intravenous glutamine (L-alanyl-L-glutamine dipeptide) infusion 
at 12  ml/hour to provide 0.5  g/kg glutamine (a total of 38.8  g/
day). Intravenous glutamine infusion was administered until day 
11. Glutamine supplementation of parenteral nutrition is a grade A 
recommendation by all expert guidelines as it can improve survival 
in a critically ill patient.1,2 A parenteral glutamine dose of 0.5 g/kg 
appears to be optimal for survival and beneficial outcomes have 
been reported in several studies.1 As this patient was still on high 
doses of inotropes, total parenteral nutrition (TPN) was also ordered 
on admission to provide early nutritional support. TPN was given at 
70 ml/hour, providing 14.6 g N, 1 505 kcal non-protein energy, 190 g 
dextrose, 76 g lipid and 10.2 g glutamine. The intravenous glutamine 
was then reduced to 9 ml/hour to continue glutamine administration 
at 0.5 g/kg. Starting energy requirements were calculated as 84 kJ/
kg (20 kcal/kg) and 1.5 g/kg of protein.
As illustrated in Table II, the patient received TPN and intravenous 
glutamine on days 0 and 1. On day 2, the patient was 
haemodynamically stable and trophic feeds, containing glutamine, 
antioxidants and tributyrin, were started via nasogastric tube at 
10 ml/hour, together with TPN, and increased to 20 ml/hour on day 
4. This provided enteral glutamine at 0.38 g/kg, in addition to the 
intravenous glutamine of 0.5  g/kg. An enteral dose of glutamine, 
greater than 0.3 g/kg, is required for benefit to be achieved.1 In the 
literature, it is not clear if enteral glutamine should be administered in 
addition to intravenous glutamine. In this case, the enteral glutamine 
was given in addition to the intravenous glutamine from days 2-6. 
Enteral nutrition has become a recommended standard of care for 
ICU patients who are haemodynamically stable within 24-48 hours 
of arrival in ICU.1
TPN, together with trophic feeds, was given until day 6. By day 7, 
enteral nutrition was started and the TPN was weaned. A high-protein, 
high-energy polymeric feed (75 g protein/l and 6 300 kJ/l) was used 
to meet the calculated nutritional requirements of the patient. The 
feed did not provide enteral glutamine. Therefore, enteral glutamine 
administration had stopped by day 7. The energy requirement was 
calculated using 105  kJ/kg (25  kcal/kg) and protein as 1.5  g/kg. 
By day 9, the patient was on full enteral nutrition at a target rate 
of 65  ml/hour, with continued intravenous infusion of glutamine 
dipeptide at 12 ml/hour (38.8 g glutamine/day, i.e. 0.5 g/kg).
On day 11, the patient was started on oral intake as he was extubated 
and fully awake. While in ICU, daily nutrient intake was calculated.
A question that is often asked by dietitians is whether the protein 
that is provided by the intravenous glutamine dipeptide should be 
added to the total protein prescription. General consensus is that 
it should not be. Table III provides a summary of the patient’s daily 
glutamine intake, as well as protein intake, with and without the 
protein content of the supplemental glutamine. The total protein 
intake, including protein from supplemental glutamine, resulted in 
intakes between 2-2.2 g protein/kg. Monitoring the serum urea gives 
a good indication of possible protein overfeeding.
The patient’s renal and liver functions were monitored throughout 
the course of ICU treatment (Table IV). Glutamine administration may 
increase blood urea nitrogen or ammonia levels in patients with 
hepatic or renal failure. According to Wischmeyer of the University of 
Colorado Health Sciences Centre,3 they tolerate blood urea nitrogen 
increases up to 12.7  mmol/l (75  mg/dl) with their patients. The 
maximum level recorded in this patient was 9.2 mmol/l.
Table III: Daily glutamine and protein intake
Day 0 1 2 3 4 5 6 7 8 9 10
Glutamine intake 
(g)
Intravenous 33.7 39.3 34.5 35.98 29.2 29.6 30.8 33.3 36.3 33.9 38.8
Enteral 0 0 6 14 24.6 24 22.8 0 0 0 0
TOTAL 33.7 39.3 40.5 50.4 53.8 50.3 50.5 33.3 36.3 33.9 38.8
Protein intake (g)
Without  glutamine protein 41 90 95 110 125 127 75 89 115 88 83
Glutamine protein added 84 133 131 149 153 151 147 124 166.5 138.2 140.5
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Supplying adequate energy and protein is the most fundamental 
form of nutritional therapy.2 The patient’s protein and energy intake 
are illustrated in Figure 1 and Figure 2 respectively. Despite several 
interruptions in feeding time because of surgical interventions, 
energy and protein intake could mostly be obtained between 80% 
and 100% of calculated requirements.
Discussion
Critical illness is associated with catabolic hormonal and cytokine 
responses, including increased levels of counter-regulatory 
hormones (cortisol, catecholamines and glucagon), increased 
levels of proinflammatory cytokines in blood and tissue [interleukin 
(IL)-1, IL-6, IL-8 and tumour necrosis factor-alpha] and peripheral 
tissue resistance to anabolic hormones (insulin and insulin-like 
growth factor 1). This hormonal milieu increases glycogenolysis and 
gluconeogenesis, causing a net breakdown of skeletal muscle and 
enhanced lipolysis to provide endogenous glucose, amino acids and 
free fatty acids that are required for cellular and organ functioning and 
wound healing.4,5 There is an increase in protein catabolism, along 
with a marked increase in urinary losses of nitrogen, phosphorus, 
sulphur, potassium, magnesium and creatinine.5 But, although these 
plasma substrate levels may be increased, their availability for use 
by peripheral tissues may be decreased and plasma levels of certain 
substrates, e.g. glutamine, may be insufficient to meet metabolic 
demands.4
Both glutamine and antioxidants have been found to play key roles 
in protecting against complications such as infections and mortality 
in surgical, trauma and critical care settings. Glutamine serves as 
a metabolic substrate for enterocytes and immune cells, and thus 
supports barrier and immune functions. Glutamine has also recently 
been proposed as a signalling molecule to turn on implicated genes 
in cell protection and immune regulation. An example of this stress-
signalling function is the role of glutamine in enhancing heat-shock 
protein, which is essential for cellular recovery following injury, and 
as protection against organ failure.1 Typically, critically ill patients 
have the most severe glutamine deficiency. Glutamine deficiency on 
admission correlates with increased mortality.1
Intravenous glutamine supplementation results in a uniform uptake 
of glutamine across the splanchic area, similar to what occurs 
with endogenously-produced glutamine. The elimination rate of 
intravenous glutamine from the plasma is fast. Uptake is also 
quick in the case of enteral glutamine supplementation and occurs 
in the upper part of the jejunum. Only a fraction of the absorbed 
glutamine can be recovered in the portal blood which is indicative of 
elimination in the gut; most likely in the enterocytes and gut immune 
cells. The complete uptake of enteral glutamine in the upper part of 
the jejunum leaves the remaining part of the gastrointestinal tract 
unsupported by the enteral route. Enteral glutamine supplementation 
has a marginal effect on plasma glutamine concentration. It is 
highly likely that, when enteral nutrition is not possible, a supply of 
parenteral glutamine becomes critical for the intestinal tract.6
It is recommended that ICU patients should be fed within 24-48 hours 
of admission, preferably via the enteral route.1 Enteral nutrition can 
be contraindicated in approximately 10-15% of critically ill patients. 
Generally recognised indications of TPN include small bowel 
Table IV: Biochemistry (renal and liver functions)
Day 0 1 2 3 4 5 6 7 8 9 10 11 12 Normal value
Serum urea (mmol/l) 7.6 7.1 6 7.1 6.2 6.3 7.1 7.5 7.9 9.2 8.7 8.9 7 2.6-7.0
Serum creatinine (µmol/l) 126 89 75 81 66 72 81 70 85 76 59 66 70 60-100
Total bilirubin (µmol/l) 13 20 18 12 9 0-21
Conjugated bilirubin (µmol/l) 7 5 0-6
GGT (U/L) 47 498 335 1-24
ALT (U/L) 103 183 128 5-40
AST (U/L) 354 173 112 8-20
ALP (U/L) 110 414 373 40-120
ALP:  alkaline phosphatase, ALT: alanine aminotransferase, AST: aspartate aminotransferase, GGT: gamma glutamyl transferase
%: percentage
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resection, proximal high output fistulae and a perforated small bowel. 
Other conditions in which enteral nutrition may be contraindicated 
or not tolerated are severe diarrhoea or emesis, substantial 
abdominal distension, partial or complete bowel obstruction, severe 
gastrointestinal bleeding and severe haemodynamic instability.4
It has become increasingly clear that the underutilised gut can 
contribute significantly to the proinflammatory state of critically ill 
patients, thus emphasising the role of early enteral nutrition.7 Enteral 
nutrition supports the functional integrity of the gut by maintaining 
tight junctions between the intraepithelial cells, and stimulating 
blood flow inducing the release of trophic endogenous agents, 
such as cholecystokinin, gastrin, bombesin and bile salts.8 Evidence 
suggests that as little as 25-50% of energy that is supplied via the 
gut generally suffices to maintain at least some of the enterally 
fed mucosal immune morphology, such as maintaining mucosal 
immunoglobulin (Ig) A levels.9 The changes seen with decreased 
enteral stimulation in extraintestinal mucosal immune parameters, 
such as decreased IgA in the respiratory tract, indicate that the 
gut-associated lymphoid tissue, as well as the mucosal-associated 
lymphoid tissue, are affected by the type and route of nutrition.8,9 The 
adverse consequences of critical illness on the reported permeability 
changes include an increased bacterial challenge (engagement 
of gut-associated lymphoid tissue with enteric organisms), the 
risk of systemic infection and a greater likelihood of multi-organ 
dysfunction syndrome.8
The specific reasons for providing early enteral nutrition are to 
maintain gut integrity, modulate stress and the systemic immune 
response and attenuate disease severity. Additional end-points 
of enteral nutrition therapy include use of the gut as a conduit for 
the delivery of immune-modulating agents and the use of enteral 
formulations as an effective means of stress ulcer prophylaxis.8
Optimal energy homeostasis should be an important goal in ICU 
patients. Both excessive and insufficient energy intake can be 
deleterious.10 When enteral intake alone was inadequate for patients 
who were expected to be mechanically ventilated for more than 
72 hours, and who had BMI scores of < 25 or < 35, each additional 
1 000 kcal/day or 30 g protein/day was reported to be associated 
with reduced mortality.1,2 The goal of protein provision is to maximise 
protein synthesis in the hope of meeting or matching catabolism. 
Efforts to reach nitrogen balance are important, but it is unrealistic 
to expect a positive balance and net increases in lean body mass.6
The goals of nutrition support therapy have been expanded from 
simply providing protein and energy to pursuing broader avenues 
for therapeutic interventions, such as pharmaconutrition and 
immune modulation.7 Glutamine has been shown to be beneficial 
in improving outcomes in clinical trials in a wide range of patients.3 
A multidisciplinary approach to nutrition support is essential.7 
Findings from a study by Roberts et al suggest that length of stay in 
the ICU is most likely to have an inverse relationship with adequacy 
of nutritional support, when nutritional support is started in ICU, 
gastrointestinal dysfunction, and time of intervention by the dietitian 
during ICU. Intervention by a registered dietitian within the first three 
days resulted in a trend towards a shorter ICU stay.11
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